Study of the Influenza Vaccine (Split Virion, Inactivated) Northern Hemisphere 2009-2010 Formulation (Intradermal Route)

Influenza Clinical Trial

Official title:

Immunogenicity and Safety of the Influenza Vaccine (Split Virion, Inactivated), Northern Hemisphere 2009-2010 Formulation (Intradermal Route)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00945438
• Other study ID #: GID29
• Status: Completed
• Phase: Phase 2
• First received: July 22, 2009
• Last updated: January 10, 2014
• Start date: May 2009
• Est. completion date: July 2009

Study information

• Verified date: January 2014
• Source: Sanofi
• Contact: n/a
• Is FDA regulated: No
• Health authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
• Study type: Interventional

Clinical Trial Summary

This study is in support of the annual application for the variation of the vaccine strains for a marketing authorisation.

Objectives:

• To evaluate compliance, in terms of immunogenicity, of the corresponding strength of the intradermal (ID) influenza vaccine Northern Hemisphere (NH) 2009-2010 formulation.

• To describe the safety of the corresponding strength of the ID influenza vaccine, NH 2009-2010 formulation.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 131
• Est. completion date: July 2009
• Est. primary completion date: June 2009
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Aged 18 to 59 years (i.e., to the day before the 60th birthday) or 60 years or older (from the day of the 60th birthday) on the day of inclusion

• Provision of a signed informed consent

• Able to attend all scheduled visits and comply with all trial procedures

• For a woman of child-bearing potential: avoid becoming pregnant (use of an effective method of contraception or abstinence) for at least 4 weeks prior to vaccination, until at least 3 weeks after vaccination

• Entitled to national social security

Exclusion Criteria:

• For a woman of child-bearing potential, known pregnancy or positive urine pregnancy test at Visit 1

• Febrile illness (temperature = 38 °C) or moderate or severe acute illness/infection on the day of vaccination, according to Investigator judgment

• Breast-feeding woman

• Participation in another clinical trial investigating a vaccine, drug, medical device, or medical procedure in the 4 weeks preceding the trial vaccination

• Planned participation in another clinical trial during the present trial period

• Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic corticosteroids therapy

• Known systemic hypersensitivity to eggs, chicken proteins, neomycin, formaldehyde and octoxynol-9, or to any of the vaccine components, or history of a life-threatening reaction to the trial vaccine or a vaccine containing any of the same substances

• Chronic illness at a stage that could interfere with trial conduct or completion, in the opinion of the Investigator

• Current alcohol abuse or drug addiction that may interfere with the subject's ability to comply with trial procedures

• Receipt of blood or blood-derived products in the past 3 months, that might interfere with the assessment of immune response

• Receipt of any vaccine in the 4 weeks preceding the trial vaccination

• Planned receipt of any vaccine in the 3 weeks following the trial vaccination

• Previous vaccination against influenza in the previous 6 months

• Thrombocytopenia, bleeding disorder or anticoagulants in the 3 weeks preceding inclusion

• Known human immunodeficiency virus (HIV), Hepatitis B surface (HBs) antigen or Hepatitis C seropositivity

• Subject deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized without his/her consent

• Employees of the investigator or study center, with direct involvement in the proposed study or other studies under the direction of that investigator or study center, as well as family members of the employees or the investigator

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

• Influenza
• Influenza, Human

Intervention

Biological:
• Influenza virus vaccine 2009-2010 formulation
0.1 mL, Intradermal
• Influenza virus vaccine 2009-2010 formulation
0.5 mL, Intradermal

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Sanofi Pasteur, a Sanofi Company

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To provide information concerning the immunogenicity of Intradermal (ID) Influenza vaccine (split virion, inactivated), NH 2009-2010 formulation.		21 days post-vaccination	No
Primary	To provide information concerning the safety of Intradermal (ID) Influenza vaccine (split virion, inactivated), NH 2009-2010 formulation.		21 days post-vaccination and entire study duration	Yes

External Links

•   Link
•   Link